Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Diversity
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
Paul Johns
PipCast®
PTE
Trade Marks
Webinars

Elanco Sheepish as Patent Application Not Inventive

by , , | Jul 11, 2024

Date of decision: 14 June 2024
Court: Federal Court of Australia
Judge: Justice Burley
Date of decision:
Court:
Judge:
14 June 2024
Federal Court of Australia
Justice Burley

This recent decision handed down by Justice Burley in Elanco Australasia Pty Ltd v Abbey Laboratories Pty Ltd [2024] FCA 640 on 14 June 2024 is the latest example of the ballooning number of patent decisions regarding Australia’s agricultural sector.  Burley J’s decision highlights the key considerations for inventive step, including (a) defining the nature of the invention; and (b) the role of expert evidence in determining the common general knowledge.

Background to the Elanco Appeal
Elanco Australasia Pty Ltd (Elanco) appealed from two decisions of the Commissioner of Patents allowing an opposition by Abbey Laboratories Pty Ltd (Abbey) to the grant of AU2014280848 entitled “Ectoparasitic treatment method and composition” (the Elanco Application).  The Elanco Application related to methods of treating biting lice on sheep and goats using the insecticide thiacloprid.  The first opposition decision related to the Elanco Application in unamended form and the second opposition decision related to the Elanco Application in amended form, the amendments being designed to overcome the Delegate’s findings in the first opposition decision.

The First and Second Abbey Oppositions
In the first opposition filed in August 2018, Abbey alleged that the Elanco Application should not proceed to grant on multiple grounds: lack of clear enough and complete enough disclosure, lack of support; lack of clarity; lack of novelty; lack of inventive step; and secret use.  In a decision handed down on 4 June 2020, Abbey succeeded on the grounds of lack of support (claims 1 – 10), lack of novelty (claims 1 and 4 – 11) and lack of inventive step (claims 1 – 3, 6 and 7).

In the second opposition commenced in July 2020, Abbey alleged only lack of inventive step against the amended Elanco Application, and ultimately succeeded on this ground in a decision handed down on 26 July 2021.

In August 2021, Elanco appealed the inventive step finding in both the first and second opposition decisions.  However, the parties ultimately agreed that:

  1. the sole issue between them was whether the amended Elanco Application involved an inventive step in light of the common general knowledge and the content of a Trade Advice Notice (published in February 2013) related to an application by Bayer Australia Ltd (Animal Health) for the registration of a new product called “Piranha Dip for Sheep” containing thiacloprid (480 g/L); and
  2. this issue could be determined by examination of claim 1 on the basis that none of the other claims would involve an inventive step if claim 1 did not.

Burley J Finds Elanco Invention Obvious
In his decision handed down on 14 June 2024, Justice Burley upheld the second opposition decision, finding the invention claimed in claim 1 to be obvious i.e. to lack an inventive step.  His Honour held that:

  • the evidence showed that the process of ascertaining a dose level range was routine to the skilled team and that it would be conducted at the proof of concept stage;
  • the skilled team would be confident, in commencing its proof of concept studies, that it would obtain an efficacious backlining treatment using thiacloprid; and
  • on the basis of the promising information in the Trade Advice Notice, the skilled team would, if it did not find an efficacious dose in initial proof of concept studies, vary the range until they did.

This decision continues the upward trend we are seeing in patent disputes between competitors in the agricultural sector.  Justice Burley’s decision highlights the key considerations the Court takes into account when determining the question of inventive step.  In particular, Justice Burley’s decision highlights the central importance of defining the nature of the invention and the role of expert evidence in determining what is the scope of the common general knowledge and whether or not the claimed invention involves an inventive step. No appeal has been filed.

About Pearce IP

Pearce IP is a boutique firm offering intellectual property specialist lawyers, patent attorneys and trade mark attorneys to the life sciences industries (in particular, pharmaceutical, biopharmaceutical, biotech, ag-tech and food tech).  Pearce IP is the 2021 ‘Intellectual Property Team of the Year’ (Lawyers Weekly Australian Law Awards) and was shortlisted for the same award in 2022.  Pearce IP is ranked in IAM Patent 1000 and Managing IP (MIP) IP Stars, in Australasian Lawyer 5 Star Awards as a ‘5 Star’ firm, and the Legal 500 APAC Guide for Intellectual Property.

Our leaders have been recognised in virtually every notable IP listing for their legal, patent and trade mark excellence including: IAM Patent 1000, IAM Strategy 300, MIP IP Stars, Doyles Guide, WIPR Leaders, 5 Star IP Lawyers, Best Lawyers, and Australasian Lawyer 5 Star Awards, and have been honoured with many awards including Australian Law Awards – IP Partner of the Year, Women in Law Awards – Partner of the Year, Women in Business Law Awards - Patent Lawyer of the Year (Asia Pacific), Most Influential Lawyers (Changemaker), among other awards.

 

Chris Vindurampulle PhD

Chris Vindurampulle PhD

Executive, Patent & Trade Mark Attorney

Chris is a senior Patent and Trade Mark Attorney who is registered to practice before the intellectual property offices of Australia and New Zealand.  He is experienced in patent drafting, patent and trade mark prosecution and opposition, and freedom to operate, opinion and due diligence work.  Through his experience and delivery of highly-regarded client service, Chris has been recognised as a leading patent practitioner having been listed in the IAM Patent 1000 as a recommended individual for patent prosecution, and a Rising Star in 2021, 2022 and 2023 by Managing IP.

Naomi Pearce

Naomi Pearce

CEO, Executive Lawyer (AU, NZ), Patent & Trade Mark Attorney (AU, NZ)

Naomi is the founder of Pearce IP, and is one of Australia’s leading IP practitioners.   Naomi is a market leading, strategic, commercially astute, patent lawyer, patent attorney and trade mark attorney, with over 25 years’ experience, and a background in molecular biology/biochemistry.  Ranked in virtually every notable legal directory, highly regarded by peers and clients, with a background in molecular biology, Naomi is renown for her successful and elegant IP/legal strategies.

Among other awards, Naomi is ranked in Chambers, IAM Patent 1000, IAM Strategy 300, is a MIP “Patent Star”, and is recognised as a WIPR Leader for patents and trade marks. Naomi is the 2023 Lawyers Weekly “IP Partner of the Year”, the 2022 Lexology client choice award recipient for Life Sciences, the 2022 Asia Pacific Women in Business Law “Patent Lawyer of the Year” and the 2021 Lawyers Weekly Women in Law SME “Partner of the Year”.  Naomi is the founder of Pearce IP, which commenced in 2017 and won 2021 “IP Team of the Year” at the Australian Law Awards.

Helen Macpherson

Helen Macpherson

Executive, Lawyer (Head of Litigation – Australia)

Helen has over 25 years’ experience as an intellectual property specialist and is recognised as an industry leader. Helen advises on all forms of intellectual property including patents, plant breeder’s rights, trade marks, copyright and confidential information.

Helen is a member of the Intellectual Property Committee of the Law Council of Australia, as well as a member of the Intellectual Property Society of Australia and New Zealand.

Get our Pearce IP Blogs & BioBlast® sent directly to your inbox

Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.

Our Latest News